Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report) Director Robert W. Duggan acquired 20,241 shares of the company’s stock in a transaction on Friday, November 17th. The stock was acquired at an average price of $6.10 per share, with a total value of $123,470.10. Following the acquisition, the director now owns 36,266,797 shares in the company, valued at approximately $221,227,461.70. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Pulse Biosciences Price Performance
PLSE stock traded up $0.14 during trading on Monday, reaching $6.26. The company had a trading volume of 163,369 shares, compared to its average volume of 133,595. Pulse Biosciences, Inc. has a 52 week low of $1.65 and a 52 week high of $9.69. The business has a 50 day moving average of $4.51 and a 200 day moving average of $5.98. The company has a market cap of $344.24 million, a P/E ratio of -7.23 and a beta of 1.25.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on shares of Pulse Biosciences in a report on Thursday, October 5th. They issued a “sell” rating on the stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN grew its stake in Pulse Biosciences by 99.9% in the second quarter. Wells Fargo & Company MN now owns 17,397 shares of the company’s stock worth $125,000 after purchasing an additional 8,694 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Pulse Biosciences by 107,258.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 12,883 shares of the company’s stock worth $93,000 after acquiring an additional 12,871 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Pulse Biosciences in the 2nd quarter worth about $76,000. Goldman Sachs Group Inc. purchased a new position in Pulse Biosciences during the 2nd quarter valued at about $74,000. Finally, Tower Research Capital LLC TRC bought a new stake in Pulse Biosciences during the second quarter worth about $68,000. Hedge funds and other institutional investors own 6.62% of the company’s stock.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
- Five stocks we like better than Pulse Biosciences
- How to Invest in Canada for Beginners
- The most upgraded stocks in November have two things in common
- What Does Downgrade Mean in Investing?
- Monday.com rocked earnings like it’s the weekend
- Industrial Products Stocks Investing
- Plan to own one retailer? Make it this one
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.